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Abstract:  The aim of this study was to prove our hypothesis that adult rats with lowering of body weight gain, rats at
12 weeks of age as an example, are suitable for evaluation of myelotoxicity.  Age-related differences between young
rats (6-week-old study) and adult rats (12-week-old study) were analyzed in hematological examination values.  The data
of the young rats were reprinted from our previous report (Miyata et al., 2009) since our hypothesis was verified by
comparison with that previous report.  Several experimental groups were defined for the 12-week-old study as well as
for the 6-week-old study; these included 5-fluorouracil (5-FU) treated groups receiving 12, 15 and 18 mg/kg/day (FU12,
FU15 and FU18), pair-feeding groups (R12, R15 and R18 receiving the same amount of food as in the FU12, FU15 and
FU18 groups, respectively) and a nontreated control group.  Numerous hematologic and bone marrow parameters in the
5-FU treated groups were comparable to those in the corresponding pair-feeding groups in both age studies.  Generally,
the influences of undernutrition were more apparent in the young rats than in the adult rats.  Histopathological
examinations showed a decrease in hematopoiesis in the bone marrow in the 5-FU treated and pair-feeding groups.  No
apparent differences were observed in the decreased hematopoiesis between the 5-FU treated and pair-feeding groups in
the 6-week-old study, but a difference between these groups was noted in the 12-week-old study; decreased
hematopoiesis was more frequently noted in the 5-FU treated groups.  These facts suggest that adult rats are more
suitable than young rats for evaluation of 5-FU-induced myelotoxicity.    (J Toxicol Pathol 2009; 22: 153–166)
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Introduction
A short-term repeated dose toxicity study conducted for
14 days is often used to predict the appropriate doses of test
articles in subsequent long-term studies or to search for
target organs of toxicity.  The rat is a widely used animal
model for safety assessments of such things as
pharmaceuticals.  Dosing is generally initiated in animals
that are approximately 6 weeks of age.  Rats of this age are
easy to obtain and economical.  Various administration
periods, such as those used in subacute, chronic and
carcinogenicity studies, are necessary to assess the safety of
a new drug.  In carcinogenicity studies, it is recommended
that dosing of the rodents should begin as soon as possible
after weaning and acclimatization and preferably before the
animal reaches 6 weeks of age1.  Generally, the age of the
animals used in the short-term repeated dose toxicity study is
similar to that of the animals used in carcinogenicity studies.
The weight of a male rat increases throughout much of its
life.  In particular, rapid weight gain occurs up until 10
weeks after birth2.  Young rats at this stage of growth are
often used in the short-term repeated dose toxicity study, and
suppression of body weight gain and decreased food
consumption are often recognized in drug administration
groups in this toxicity study.  Consequently, whether
hematology, bone marrow cytology or histopathological
changes are caused directly by the drug or indirectly by
suppression of body weight gain and decreased food
consumption can be difficult to evaluate.
We previously reported that many of the influences of
dietary restriction on hematological examination values
were comparable to those caused by 5-fluorouracil (5-FU)
administration in young rats (6 weeks of age at start of the
experiment)3.  In fact, undernutrition during the rapid growth
stage is thought to cause changes, such as hemocytopenia,
that are nearly equal to those induced by immunotoxicants.
Many reports concerning hematological changes in dietary
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restricted rats4–9 or nontreated rats with age-related
physiological data10–13 have been published.  However, few
reports have examined age-related hematological changes in
dietary restricted rats.  In this study, we set out to prove our
hypothesis that adult rats with lowering of body weight gain,
rats at 12 weeks of age as an example, are suitable for
evaluation of myelotoxicity.  Our hypothesis was verified by
comparison with our previous report3.
The anti-cancer drug 5-FU belongs to a category of
chemotherapy agents called antimetabolites and functions as
a pyrimidine analog14,15; the myelotoxic effect of 5-FU on
bone marrow is a serious adverse effect associated with its
clinical use16.  We selected 5-FU as a positive control, since
this agent is known to cause blood toxicity and bone marrow
depression17–20.
In this study, 5-FU treated and pair-feeding groups
(animals were given the same amount of food as the average
amount of food consumption in the 5-FU treated groups)
were used for the experimental design.  We compared the
hematological, bone marrow cytological and
histopathological results of the 5-FU treated and pair-
feeding groups after a 14-day administration period and after
a 7-day recovery period.  Thereafter, age-related differences
between the young rats (6 weeks of age at start of the
experiment) and adult rats (12 weeks of age at start of the
experiment) were analyzed.  The data of the young rats used
for the age-related differences were reprinted from our
previous report3.  Here, we discuss the age-related
differences in hematological and/or myelotoxic effects under
decreased food consumption based on examinations of
general toxicity studies.  This study provides useful indices
for evaluating myelotoxicity when suppression of body
weight gain and decreased food consumption are noted in
toxicity studies.  Our hypothesis that adult rats may be
suitable for evaluation of myelotoxicity was verified by
comparison of age-related differences.
Materials and Methods
Chemicals and dose selection rationale
The 5-FU was purchased from Wako Pure Chemical
Industries Ltd. (Osaka, Japan) and was dissolved in water for
injection for dosing.  All other chemicals and regents were
purchased from commercial sources.
In a previous 14-day dose-finding study involving oral
administration of 10 and 30 mg/kg/day of 5-FU in 6-week-
old rats, all the animals given 30 mg/kg died on Days 10 to
13; meanwhile, no abnormalities in body weight,
hematology, bone marrow cytology and so on were observed
in the group dosed with 10 mg/kg.  In an additional 5-day
dose-finding study involving oral administration of 20 and
25 mg/kg/day of 5-FU in 5- or 6-week-old rats, body weight,
food consumption and the marrow nucleated cell count were
remarkably decreased in the 25 mg/kg dosing group and
slightly decreased in the 20 mg/kg dosing group.  Therefore,
dosages of 12, 15 and 18 mg/kg/day were chosen for use in
this study.
Animals and housing conditions
A total of 84 male Crl:CD(SD) rats were purchased
from Charles River Japan Inc.  (Tsukuba, Ibaraki, Japan).
The animals were housed individually in stainless steel cages
(W:225 mm × D:350 mm × H:200 mm) with an artificial
lighting cycle of 12 hours (7:15 to 19:15), a temperature of
23 ± 3°C, a relative humidity of 50 ± 20% and a ventilation
cycle of 10 to 20 times/hour.  Before group assignment, all
the animals were allowed free access to a standard laboratory
animal chow (MF; Oriental Yeast Co., Ltd., Tokyo, Japan)
and drinking water.  After group assignment, the R12, R15
and R18 groups described below were given restricted diets.
At the start of dosing / pair feeding, the animals were 12
weeks of age.
All the animals were treated in accordance with the
recommendations of the Guide for the Care and Use of
Laboratory Animals of Taisho Pharmaceutical Co., Ltd.
Study groups
The experimental design is shown in Fig. 1.  The
animals were divided into the following 7 groups: NT,
FU12, FU15, FU18, R12, R15 and R18.  The animals used
were as follows: 12 rats / group; 6 rats per group were
euthanized at the end of the administration and recovery
periods, respectively.  The animals in the NT group were
nontreated and were allowed free access to a standard
laboratory animal chow; this group was used as the control
group.  The animals in the FU12, FU15 and FU18 groups
were orally treated with 5-FU for 14 consecutive days at
doses of 12, 15 and 18 mg/kg, respectively.  The dose
volume was set at 10 mL/kg body weight and was calculated
based on the most recent body weight.  The animals in the
R12, R15 and R18 groups were not given 5-FU, but were
given amounts of food equal to those consumed by the rats in
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the FU12, FU15 and FU18 groups, respectively.  If all the
food was not consumed in any of the R12, R15 or R18
groups, the next portion of food was supplied without
removing the food that had not been consumed.  The next
day of initial administration of 5-FU was set as a start date of
pair-feeding.  After an administration period of 14 days in
the 5-FU treated groups, the recovery period was set at 7
days, which is considered appropriate to examine the
reversibility of changes, and administration was withdrawn
during this period.
Examinations and methods
The starting day of 5-FU administration or pair-feeding
was designated as Day 0 in this study.  Body weight and food
consumption were measured every day during the
administration and recovery periods in each animal.  The
ratio of the amount of limited food was calculated using the
following formula: fu / nt -100, where fu represents the total
amount of food consumption in each 5-FU group × 100 and
nt represents the total amount of food consumption in the NT
group.  In the 5-FU treated groups, abnormal eating behavior
(spilled food) was observed from Day 4 to Day 17 in many
rats.  Therefore, food consumption in the 5-FU treated
groups was corrected using the amount of spilled food.  The
following examinations were performed in all the animals
(excluding those that died unexpectedly) at the end of the
administration period (6 rats/group) or at the end of the
recovery period (6 rats/group), respectively.  The animals
were fasted for at least 16 hours prior to necropsy, and blood
samples were collected via the abdominal aorta under ether
anesthesia into dipotassium ethylenediaminetetraacetic acid
(EDTA-2K) treated tubes for the hematological
examination.  The complete blood count (CBC) and
differential white blood cell count were measured using a
hematology analyzer Technicon H·1E (Bayer Medical Ltd.,
Tarrytown, NY, USA).  The percentage of reticulocytes was
measured using a flow cytometer (EPICS-XL; Beckman
Coulter Inc., Fullerton, CA, USA) with Coriphosphine-O
stain.  After blood sampling, all the animals were euthanized
by exsanguination.  For the marrow cytological evaluation,
the right side femur was obtained and used.  The bone
marrow nucleated cell count was measured using the above-
mentioned hematology analyzer.  The differential cell count
was determined by counting 500 cells in bone marrow
smears stained with May-Grünwald and Giemsa.  Then, the
absolute numbers of each type of marrow cell (myeloid,
erythroid, lymphoid and other cells) were calculated using
the data for the marrow cell number and marrow differential
counts.  The spleen and thymus were weighed, and the ratios
of these organ weights to the body weight (relative weights)
were calculated based on the final body weight.  For the
histopathological evaluation, the left side femur (bone
marrow), liver, spleen, kidney, thymus, adrenal, stomach,
duodenum, ileum and colon were fixed in 10% neutral
buffered formalin.  The femur was decalcified by the Plank-
Rychlo method.  After fixation, hematoxylin and eosin
(H&E) stained specimens were prepared and subjected to
microscopic observation.
Statistical analysis
Significant differences between the NT and 5-FU
treated groups or between the NT and pair-feeding groups
were analyzed using the following procedure.  The
homogeneity of the variance among the groups was first
tested using a Bartlett’s test.  When a homogenous variance
was noted, all the groups were compared using a one-way
analysis of variance.  When a heterogeneous variance was
noted, the Kruskal-Wallis test was subsequently performed.
Finally, the Dunnett’s test (if homogeneous) or Dunnett’s-
type multiple comparison test (if heterogeneous) was used if
a significant difference was noted between the groups.
Significant differences between the 5-FU treated and
pair-feeding groups (i.e., FU12 vs. R12, FU15 vs. R15, or
FU18 vs. R18) were analyzed using the following procedure.
The homogeneity of the variance among the groups was first
tested using the F-test, and then the Student’s t-test (if
homogeneous) or Aspin-Welch’s t-test (if heterogeneous)
was performed.
The Bartlett’s test, one-way analysis of variance,
Kruskal-Wallis test and F-test were conducted using a
significance level of 5% (two-tailed except for the F-test,
which was one-tailed), while the other tests were conducted
using significance levels of 1% and 5% (two-tailed).  A
statistical analysis of clinical observation, necropsy and
histopathology results was not performed.
Analysis of age-related differences
The degree of variability (relative standard deviation:
RSD) of the main inspection values in the NT group were
below about 20%.  The variation of each group from the NT
group (relative error: RE) was calculated in this study
(hereinafter referred to as 12-week-old study).  RE was
similarly calculated for the numerical data of our previous
report3 (hereinafter referred to as 6-week-old study), and
when the difference in the subtracted RE value of the 6-
week-old study from the 12-week-old study was 20% or
more, a significant change was assumed.
Results
Mortality and clinical signs
One rat in each of the FU12 and FU15 groups died on
Day 13.  A subcapsular hemorrhagic cyst in the kidney and a
marked subungual hemorrhage of the forelimb were seen in
the animals that died in the FU12 and FU15 groups,
respectively.  Alopecia was seen in one rat in each of the
FU12 and FU15 groups, and loose stools were seen in a few
rats in the FU18 group.  Animals that died unexpectedly
were not included in the assessments of hematology, bone
marrow cytology and organ weight performed at the end of
the administration and/or recovery periods.
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Food consumption (Fig. 2)
In the 5-FU treated groups, a decrease in food
consumption was seen during the administration period.  The
decrease in food consumption recovered during the recovery
period and was immediately comparable to that in the NT
group.  At the end of the administration period, the ratios of
the total amount of food consumption in each 5-FU treated
group (FU12, FU15 and FU18), compared with the NT
group, were 38%, 56% and 65%, respectively.  At the end of
the recovery period, the ratios of the total amount of food
consumption (during the administration and recovery
periods) in each 5-FU treated group (FU12, FU15 and
FU18), compared with the NT group, were 27%, 45% and
52%, respectively.
In the pair-feeding groups, a few rats left some food
behind during the early stage of the administration period but
subsequently consumed all the available food thereafter.
The food was consumed within about one hour in the pair-
feeding groups.
Body weight (Fig. 3)
In the 5-FU treated and pair-feeding groups, a decrease
in body weight was seen during the administration period.
Thereafter, the body weight gain recovered during the
recovery period.  The body weights in the pair-feeding
groups showed similar patterns to those in the 5-FU treated
groups.
Hematology (Figs. 4 and 5)
At the end of the administration period, decreased white
blood cell count was not observed in this 12-week-old study,
though a decrease in the white blood cell count (with an
Fig. 2. Food consumption changes in the 5-FU treated groups during the administration and recovery periods.  Data are expressed
as percentages relative to the NT group and were calculated using the mean values for each group.  The data of the 6-
week-old study were reprinted from our previous report3.  In the 5-FU treated groups, a decrease in food consumption was
seen during the administration period in both the 6- and 12-week-old studies.  The decrease in food consumption
recovered during the recovery period and was immediately comparable to that in the NT group.Asanuma, Miyata, Iwaki et al. 157
unchanged differential count) was observed in the FU15,
FU18 and R18 groups in the 6-week-old study3.  A decrease
in reticulocytes was observed in the FU12, FU15, FU18,
R12, R15 and R18 groups.  At the end of the recovery period,
a change in reticulocytes that exceeded the normal level was
observed in the FU15 and FU18 groups, though a decrease or
increase in reticulocytes was not seen in the pair-feeding
groups.  In addition, an increase in platelets was observed in
the FU12, FU15 and FU18 groups.
At the end of the administration period, an increase in
hemoglobin was observed in the FU15, FU18, R12, R15 and
R18 groups, but no apparent difference was observed
between the 5-FU treated and pair-feeding groups.  Increases
in the red blood cell and hematocrit levels related to an
increase in hemoglobin were seen in the pair-feeding groups.
The elevated values recovered at the end of the recovery
period; however, decreased hemoglobin, red blood cell and
hematocrit levels were observed in the FU15 and/or FU18
groups.
Bone marrow cytology (Fig. 6)
At the end of the administration period, a decrease in
myeloid cells was not observed in this 12-week-old study,
though a decrease in myeloid cells was observed in the
FU15, FU18 and R18 groups in the 6-week-old study3.  A
decrease in erythroid cells was noted in the FU18, R12, R15
and R18 groups, while a decrease in lymphoid cells was
noted in the FU18 and R18 groups; no apparent differences
between the 5-FU treated and pair-feeding groups were
observed.  A high M/E ratio was observed in the FU18, R15
and R18 groups.  Abnormal granulocytes with
hypersegmented nuclei and/or polyploidy nuclei (with a
frequency of 1% or less) were only observed in the 5-FU
treated groups (Fig. 7).  At the end of the recovery period, the
changes observed at the end of the administration period
were reduced or had disappeared.
Organ weight (Fig. 8)
At the end of the administration period, reduction in the
Fig. 3. Body weight changes in the 5-FU treated and pair-feeding groups during the administration and recovery periods.
Data are expressed as percentages relative to the NT group and were calculated using the mean values for each group.
The data of the 6-week-old study were reprinted from our previous report3.  In the 5-FU treated and pair-feeding
groups, a decrease in body weight was seen during the administration period in both the 6- and 12-week-old studies;
thereafter, the body weight gain recovered during the recovery period.  The body weights from baseline to the day
before necropsy was performed at the end of the administration period in the NT group increased from 230 g to 330
g in the 6-week-old study and from 459 g to 485 g in the 12-week-old study, respectively.158 Importance of Starting Age for Myelotoxicity Study
thymus weight was observed in the FU18 group.  The
thymus weights did not decrease in the pair-feeding groups
in this 12-week-old study, while the reduction in the thymus
weight in the FU18 group suggests the influence of 5-FU
dosing.  At the end of the recovery period, the changes
observed at the end of the administration period were
reduced or had disappeared.  In addition, an increase in the
spleen weight was observed in the FU18 group.
Necropsy
No abnormalities were seen in any group at the end of
the administration period.
Histopathology (Figs. 9 and 10, Tables 1 and 2)
Slightly decreased hematopoiesis in the bone marrow
was observed at the end of both the administration and
recovery periods in the NT group.
At the end of the administration period, decreased
hematopoiesis in the bone marrow that was indicative of an
effect of 5-FU administration or dietary restriction was
observed in the FU15, FU18 and R18 groups.  This finding
was persisted at the end of the recovery period.  A difference
between the 5-FU treated and pair-feeding groups was noted
since decreased hematopoiesis was more frequently noted in
the 5-FU treated groups.  In addition, though slight
Fig. 4. Hematological changes in white blood cells (A), reticulocytes (B) and platelets (C) at the end of the administration
(A1, B1 and C1) and recovery (A2, B2 and C2) periods.  Data are expressed as means ± S.D.  (n=5 or 6).  The data of
the 6-week-old study were reprinted from our previous report3.  Statistical significance was analyzed using the
Dunnett’s test or Dunnett’s-type test (* p<0.05, ** p<0.01), compared with the NT group.  Moreover, the differences
in values between the 5-FU treated and pair-feeding groups were analyzed using a Student’s t-test or Aspin-Welch’s
t-test (# p<0.05, ## p<0.01).Asanuma, Miyata, Iwaki et al. 159
telangiectasis in the bone marrow was observed in the FU12,
FU18 and R18 groups.  The telangiectasis disappeared at the
end of the recovery period.  No apparent differences in
telangiectasis were observed between the 5-FU treated and
pair-feeding groups.
At the end of the administration period, atrophy of the
thymus was observed in the 5-FU treated and pair-feeding
groups (data not shown).  Moreover, atrophy of the white
pulp of the spleen was observed mainly in the dead animals.
At the end of the recovery period, increased extramedullary
hematopoiesis in the spleen was found only in the 5-FU
treated groups.  Nothing of note was found in other organs.
Discussion
Age-related differences between the young rats (6-
week-old study) and adult rats (12-week-old study) were
analyzed in the hematological examination values.  The data
of the young rats were reprinted from our previous report3
since our hypothesis was verified by comparison with that
previous report.  In the 5-FU treated groups, a decrease in
food consumption was seen during the administration period
in both the 6- and 12-week-old studies.  The body weights in
the pair-feeding groups were comparable to those in the 5-
FU treated groups in both studies.  The degree of decreased
Fig. 5. Hematological changes in hemoglobin (A), red blood cells (B) and hematocrit (C) at the end of the administration
(A1, B1 and C1) and recovery (A2, B2 and C2) periods.  Data are expressed as means ± S.D.  (n=5 or 6). The data of
the 6-week-old study were reprinted from our previous report3. Statistical significance was analyzed using the
Dunnett’s test or Dunnett’s-type test (* p<0.05, ** p<0.01), compared with the NT group.  Moreover, the differences
in values between the 5-FU treated and pair-feeding groups were analyzed using a Student’s t-test or Aspin-Welch’s
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Fig. 6. Bone marrow cytological changes in myeloid cells (A), erythroid cells (B), lymphoid cells (C) and M/E ratio (D) at
the end of the administration (A1, B1, C1 and D1) and recovery (A2, B2, C2 and D2) periods.  Data are expressed as
means ± S.D. (n=5 or 6). The data of the 6-week-old study were reprinted from our previous report3. Statistical
significance was analyzed using the Dunnett’s test or Dunnett’s-type test (* p<0.05, ** p<0.01), compared with the
NT group. Moreover, the differences in values between the 5-FU treated and pair-feeding groups were analyzed
using a Student’s t-test or Aspin-Welch’s t-test (# p<0.05, ## p<0.01).Asanuma, Miyata, Iwaki et al. 161
Fig. 7. Bone marrow cytology.  Representative images of the NT group in the 6-week-study (A) and the 5-FU treated groups in the 6-week-old
(B, C and D) and 12-week-old (E and F) studies are shown. The images of the 6-week-old study were reprinted or reshot from the slides in
our previous report3. In the 5-FU treated groups at the end of the administration period, granulocytes with hypersegmented nuclei (B) or
polyploidy nuclei (C, D, E and F) were observed, and the frequency in the marrow nucleated cells was 1% or less. May-Grünwald and
Giemsa stain. Original magnification: × 1,000. Bar = 10 μm.
Fig. 8. Relative organ weight changes in the thymus (A) and spleen (B) at the end of the administration (A1 and B1) and recovery (A2 and B2)
periods.  Data are expressed as means ± S.D. (n=5 or 6). The data of the 6-week-old study were reprinted from our previous report3.
Statistical significance was analyzed using the Dunnett’s test or Dunnett’s-type test (** p<0.01), compared with the NT group. Moreover,
the differences in values between the 5-FU treated and pair-feeding groups were analyzed using a Student’s t-test or Aspin-Welch’s t-test
(## p<0.01).162 Importance of Starting Age for Myelotoxicity Study
food consumption was remarkable in the 12-week-old study.
On the other hand, the degree of decreased body weight was
remarkable in the 6-week-old study.  In young animals that
are still growing, energy is necessary not only for
maintaining their body, but also for growth.  Therefore, the
young rats were perhaps more susceptible to body weight
loss in response to a reduction in food consumption.
In this study, the following granulocytic or lymphocytic
changes were considered to be characteristic of age-related
differences.  Decreases in peripheral white blood cells and
marrow myeloid cells were observed in the 5-FU treated and
pair-feeding groups at the end of the administration period
only in the 6-week-old study.  In addition, reductions in the
thymus weight in the pair-feeding groups were only
observed in the 6-week-old study.  Decreased peripheral
white blood cells and reductions in thymus weight showed a
strong effect of undernutrition, since no apparent differences
were observed between the 5-FU treated and pair-feeding
groups or the changes were only observed in the pair-feeding
groups.  No decrease in the white blood cell count was
observed in the 12-week-old study.  However, the influence
of 5-FU was significant in the 12-week-old study.  The
degree of decreased food consumption and the number of
deaths were remarkable or comparable in the 12-week-old
study.  The immune system, with its ongoing cellular
proliferation and differentiation, lymphocyte trafficking and
Fig. 9. Histopathology of the bone marrow at the end of the administration period.  Representative images of the NT group in the 6-week-old (A)
and 12-week-old (D) studies, the 5-FU treated groups in the 6-week-old (B) and 12-week-old (E) studies and the pair-feeding groups in
the 6-week-old (C) and 12-week-old (F) studies are shown. The images of the 6-week-old study were reprinted or reshot from the slides in
our previous report3. The images marked with a letter followed by a 1 indicate the low magnification: × 70. The images marked with a
letter followed by a 2 indicate the high magnification: × 140. H&E stain.  Dh: decreased hematopoiesis; not remarkable (–), slight (+) and
moderate (++) images are shown.  T: telangiectasis; not remarkable (–), slight (+) and moderate (++) images are shown.  Telangiectasis
with marked hemorrhage was categorized as severe (+++; image not shown).Asanuma, Miyata, Iwaki et al. 163
gene amplification, is highly susceptible to toxic insults,
particularly in the thymus and bone marrow where rapid cell
turnover occurs21.  For the individual dose-response
relationship, thresholds for most toxic effects certainly exist,
although interindividual variability in response and
qualitative changes in response pattern with dose make it
difficult to establish a true no-effects threshold for any
chemical22.  Since some reports on the thresholds for
changes in dietary restricted rats have been published9,23, the
changes in this study, such as the differences in the
reductions of white blood cells, suggest that the thresholds
differed according to age.
In addition, the following erythroblastic changes were
considered to be characteristic of age-related differences.  A
decrease in reticulocytes was observed at the end of the
administration period in the 5-FU treated and pair-feeding
Fig. 10.Histopathology of the spleen at the end of the recovery period.  Representative images of the NT group in the 6-week-old study
(A) and the 5-FU treated groups in the 6-week-old (B) and 12-week-old (C) studies are shown. The images of the 6-week-old
study were reshot from the slides in our previous report3. The images marked with a letter followed by a 1 indicate the low
magnification: × 28. The images marked with a letter followed by a 2 indicate the high magnification: × 70. H&E stain.  Eh:
increased extramedullary hematopoiesis; not remarkable (–), slight (+) and severe (+++) images are shown.
Table 1. Histopathological Findings of the Bone Marrow at the End of the Administration and Recovery Periods
Groups NT FU12 FU15 FU18 R12 R15 R18
Grade – + ++ – + ++ – + ++ – + ++ +++ – + ++ – + ++ – + ++
6-week-old study
   Administration period
Number of animals 6 6 6 6 a, b) 66 6
   Decreased hematopoiesis 6 0 0 5 0 1 1 4 1 0 3 3 2 4 0 3 2 1 3 2 1
   Telangiectasis 6 0 0 6 0 0 2 3 1 1 2 2 1 6 0 0 4 2 0 2 4 0
   Recovery period
Number of animals 6 6 6 5 a) 65   c) 5 c)
   Decreased hematopoiesis 6 0 0 5 0 1 3 2 1 3 1 1 5 1 0 1 4 0 0 1 4
   Telangiectasis 6 0 0 6 0 0 6 0 0 5 0 0 0 6 0 0 5 0 0 5 0 0
 12-week-old study
   Administration period
    Number of animals 6 7 a) 7 a) 66 6 6
   Decreased hematopoiesis 1 5 0 2 5 0 1 3 3 0 3 3 0 6 0 0 6 0 0 5 1
   Telangiectasis 6 0 0 5 2 0 7 0 0 5 1 0 0 6 0 0 6 0 0 5 1 0
   Recovery period
Number of animals 6 5 a) 5 a) 66 6 6
   Decreased hematopoiesis 0 6 0 1 4 0 0 2 3 0 4 2 0 6 0 0 4 2 0 3 3
   Telangiectasis 6 0 0 5 0 0 5 0 0 6 0 0 0 6 0 0 6 0 0 6 0 0
The histopathological changes in the femoral bone marrow were graded into 4 categories: not remarkable (–), slight (+), moderate (++) and severe (+++). The number of animals
affected at each grade is shown. The data of the 6-week-old study were reprinted from our previous report3. A moderate or greater reduction in hematopoiesis in the 12-week-old
study and a slight or greater reduction in hematopoiesis in the 6-week-old study were regarded as suggesting the influence of 5-FU administration or dietary restriction.
a) Animals that died were included in the administration period (therefore, the number of animals reported in the recovery period is lower). b) One animal that died in the FU18
group in the 6-week-old study was not examined histopathologically because of advanced autolysis. c) One animal in each of the R15 and R18 groups in the 6-week-old study was
not evaluated after the recovery period because of sampling failure (missing).164 Importance of Starting Age for Myelotoxicity Study
groups in both the 6- and 12-week-old studies, and the
degree of this change was remarkable in the 6-week-old
study.  Since a decrease in marrow erythroid cells was also
observed, no age-related differences were observed in this
study.  As for the reductions in reticulocytes and marrow
erythroid cells observed at the end of the administration
period, no apparent differences were observed between the
5-FU treated and pair-feeding groups in either the 6- or 12-
week-old studies.  The influence of undernutrition on
erythroblastic changes cannot be disregarded.  The plasma
erythropoietin level is known to be high in infant rats24,25.
Naeshiro et al.  reported that overnight fasting influenced the
erythropoietin level more severely in male F344 rats aged 6
weeks than those aged 10 weeks24.  The large number of
erythroblastic cells in infant rats gradually decreases26,27.
Moreover, the granulocyte/erythroid ratio (G/E ratio)
reportedly increases at 9 weeks of age and becomes a
constant value thereafter, suggesting that 9 weeks of age is
the maturational age in rats using marrow cells as an
indicator, and this transition is comparable to the sexual
maturation time of male rats26.  The influences of
undernutrition were strongly apparent on erythroblastic
changes in both the 6- and 12-week-old studies but were
more severe in the young rats (6-week-old study) in which
hematopoiesis maturation had not yet been completed.  The
histopathological examinations showed that decreased
hematopoiesis in the bone marrow attributable to
administration of 5-FU or dietary restriction was remarkable
in the 6-week-old study, but reductions in hematopoiesis
were rare in the pair-feeding groups in the 12-week-old
study.  This fact suggests that, similar to the effect on the
hematological changes, the effect of undernutrition was
small in the 12-week-old study.
In this study, the following changes were considered
characteristic of the effects of 5-FU.  Abnormal granulocytes
with hypersegmented nuclei and/or polyploidy nuclei in
morphologic observations of the bone marrow were only
noted in the 5-FU treated groups in both the 6- and 12-week-
old studies.  This change originates from the inhibition of
DNA synthesis by 5-FU.  Morphologic observations are
thought to be useful for identifying marrow toxicity since
they can reveal the direct effects of the drug.  No age-related
differences in abnormal morphologies were noted in this
study.  A decrease in marrow myeloid cells was observed
only in the 5-FU treated groups in the 6-week-old study.
Decreased hematopoiesis in the bone marrow was observed
remarkably in the 5-FU treated groups in the 12-week-old
study.  The cause of these age-related differences is
uncertain.  Histopathological examinations revealed the
presence of telangiectasis in the bone marrow in the 5-FU
treated and pair-feeding groups in both the 6- and 12-week-
old studies.  In particular, the influence of 5-FU treatment on
telangiectasis was apparent in the 6-week-old study, since
moderate or severe changes were only observed in the 5-FU
treated groups.  It has been reported that telangiectasis in the
bone marrow is caused by a blood vessel disorder28 or a
decrease in the blood cell count29.  Myeloid hypoplasia
induced by a prazosin analogue in rats has previously been
reported to result in a normal proportion of fat cells with a
reduced density of hematopoietic cells and a greatly
expanded sinusoidal volume filled with red blood cells30.  In
this study, we speculated that the telangiectasis represented
the filling of a deficit with red blood cells and that age-
related differences in its appearance might have been related
to a reduction in marrow myeloid cells.  As mentioned
above, the influence of undernutrition on erythroblastic
changes at the end of the administration period cannot be
disregarded; however, the effect of 5-FU became obvious
Table 2. Histopathological Findings of the Spleen at the End of the Administration and Recovery Periods
Groups NT FU12 FU15 FU18 R12 R15 R18
Grade – + ++ – + ++ – + ++ – + ++ +++ – + ++ – + ++ – + ++
6-week-old study
  Administration period
Number of animals 6 6 6 6 a, b) 66 6
  Increased extramedullary hematopoiesis 6 0 0 6 0 0 6 0 0 6 0 0 0 6 0 0 6 0 0 6 0 0
  Atrophy of the white pulp 6 0 0 6 0 0 6 0 0 4 1 1 6 0 0 6 0 0 6 0 0
  Recovery period
Number of animals 6 6 6 5 a) 66 6
  Increased extramedullary hematopoiesis 6 0 0 5 1 0 3 3 0 0 5 0 0 6 0 0 6 0 0 6 0 0
  Atrophy of the white pulp 6 0 0 6 0 0 6 0 0 5 0 0 6 0 0 6 0 0 6 0 0
12-week-old study
  Administration period
Number of animals 6 7 a) 7 a) 66 6 6
  Increased extramedullary hematopoiesis 6 0 0 7 0 0 7 0 0 6 0 0 0 6 0 0 6 0 0 6 0 0
  Atrophy of the white pulp 6 0 0 7 0 0 6 1 0 6 0 0 6 0 0 6 0 0 6 0 0
  Recovery period
Number of animals 6 5 a) 5 a) 66 6 6
  Increased extramedullary hematopoiesis 6 0 0 2 3 0 0 4 1 0 3 2 1 6 0 0 6 0 0 6 0 0
  Atrophy of the white pulp 6 0 0 5 0 0 5 0 0 6 0 0 6 0 0 6 0 0 6 0 0
The histopathological changes in the spleen were graded into 4 categories: not remarkable (–), slight (+), moderate (++) and severe (+++). The number of animals affected at
each grade is shown. The data of the 6-week-old study were reprinted from our previous report3.
a) Animals that died were included in the administration period (therefore, the number of animals reported in the recovery period is lower). b) One animal that died in the FU18
group in the 6-week-old study was not examined histopathologically because of advanced autolysis.Asanuma, Miyata, Iwaki et al. 165
after its withdrawal, and no age-related differences in the
detection of erythroblastic changes were observed.  At the
end of the recovery period, increased reticulocyte and/or
platelet counts with large individual variations were
observed in the FU15 group in the 12-week-old study and in
the FU18 group in both the 6- and 12-week-old studies, and
this finding was more noticeable in the 12-week-old study
than in the 6-week-old study.  In addition, increased
extramedullary hematopoiesis in the spleen with an increase
in the organ weight was found only in the 5-FU treated
groups at the end of the recovery period and was more
frequent and severe in the 12-week-old study than in the 6-
week-old study.  Extramedullary hematopoiesis tends to be
decreased in adult animals, but can increase in any animal
when there is increased demand for these cells as in the case
of anemia, inflammation, decreased production by the bone
marrow or neoplasia31.  The age-related difference of the
rebound reactions found in this study might relate to the
maturity level of the spleen and/or the degree of decreased
bone marrow hematopoiesis following 5-FU administration.
In conclusion, this study showed several characteristic
age-related differences between rats treated with 5-FU
dosing or dietary restriction.  Many of the changes observed
in the 5-FU treated rats in the 12-week-old study, as well as
those in the 6-week-old study, were thought to have been
caused by the reduction in food consumption associated with
the 5-FU treatment.  Generally, the influences of
undernutrition were more apparent in young rats (6-week-
old study) that were in a stage of active growth (increasing
body weight) and in which hematopoiesis maturation had not
yet been completed.  These facts suggest that adult rats with
lowering of body weight gain, rats at 12 weeks of age as an
example, are more suitable than young rats for evaluation of
5-FU-induced myelotoxicity.
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